"Artificial Pancreas Improves Time In Range Vs. Insulin Pump Therapy" - Regina Schaffer
Children and adults with type 1 diabetes assigned to an artificial pancreas for six months spent an average of 2.6 fewer hours per day in hyperglycemia and 13 fewer minutes per day in hypoglycemia when compared with participants using sensor-augmented insulin pump therapy, according to researchers at the Icahn School of Medicine at Mount Sinai and published in The New England Journal of Medicine. “What is so exciting about this study is that, compared with other closed-loop insulin delivery systems, we have 11 percent increased time in range, which is a least 2.6 hours per day, the frequency of hypoglycemia and hyperglycemia were reduced in all study subjects and the benefits were achieved in the first month of the study and consistently sustained throughout the 6 months of the trial,” said study author Carol Levy, MD, clinical director of the Mount Sinai Diabetes Center. She added, “The rate of use was 92 percent throughout the trial, which is huge. We really see durability of use and benefit. It was an incredibly exciting trial to be a part of for those reasons.”
— Carol Levy, MD, CDE, Clinical Director, Mount Sinai Diabetes Center, Associate Professor, Medicine, Endocrinology, Diabetes, Bone Disease, Obstetrics, Gynecology, Reproductive Science Icahn School of Medicine at Mount Sinai
Additional coverage: Specialty Medical Dialogues; Medpage Today
Artificial Pancreas System Better Controls Blood Glucose Levels than Current Technology
Oct 16, 2019 View All Press ReleasesNIH Funds First Artificial Pancreas Study in the United States for Pregnant Women
Jan 24, 2019 View All Press Releases